Pamela Atwell provides senior leadership and collaborates with colleagues in Fortrea’s Global Clinical Development department to build strategies that enable successful delivery of hematology/oncology clinical trials for our customers, with the patient and site front of mind, through the design of evidence-based study plans, study engineering and study governance.
Ms. Atwell has more than 30 years of experience in hematology/oncology clinical research. As a project director with Covance (company now known as Fortrea), she managed global Phase II and III multi-center studies in the hematology and oncology therapeutic areas. She supervised/line managed project teams, tracked timelines and budgets, and coordinated all project activities to ensure operational excellence and high quality, on-time and on-budget study delivery.
Prior to joining Covance, Pamela was a member of the Oncology/HIV, Medical Affairs department at Glaxo SmithKline (known as Glaxo Wellcome at time of employment) where she managed studies involving key compounds in the company’s oncology portfolio, including ondansetron, vinorelbine, and eniluracil.
She has created strategic delivery plans and managed studies in the regions of North America, South America, Eastern and Western Europe, Middle East, South Africa, Russia, and Asia-Pacific. In addition, she has helped plan and conduct Investigators’ Meetings in North America (including Mexico), Europe, and Asia-Pacific.
Pamela completed a one-year international assignment in Brussels, Belgium allowing her to gain invaluable hands-on trial management experience outside the US. In addition, she served as liaison across multiple clinical trials with the European Oncology Research Treatment Center (EORTC) located in Brussels.
She received her Bachelor’s Degree from The University of Virginia.